ES2091363T3 - Compuesto farmaceutico de liberacion controlada con propiedades bioadhesivas. - Google Patents

Compuesto farmaceutico de liberacion controlada con propiedades bioadhesivas.

Info

Publication number
ES2091363T3
ES2091363T3 ES92109080T ES92109080T ES2091363T3 ES 2091363 T3 ES2091363 T3 ES 2091363T3 ES 92109080 T ES92109080 T ES 92109080T ES 92109080 T ES92109080 T ES 92109080T ES 2091363 T3 ES2091363 T3 ES 2091363T3
Authority
ES
Spain
Prior art keywords
composition
controlled release
release compound
bioadhesive properties
pharmaceutical controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92109080T
Other languages
English (en)
Inventor
Giancarlo Santus
Giuseppe Bottoni
Giovanni Sala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Recordati SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA filed Critical Recordati SA
Application granted granted Critical
Publication of ES2091363T3 publication Critical patent/ES2091363T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Abstract

SE DESCRIBE UNA COMPOSICION FARMACEUTICA PARA LA DISTRIBUCION CONTROLADA DE FARMACOS MEDICINALES, QUE TIENE LA PROPIEDAD DE ADHERIRSE A LOS TEJIDOS BIOLOGICOS. LAS CARACTERISTICAS PECULIARES DE LA COMPOSICION SON UNA PLURALIDAD DE UNIDADES DE PEQUEÑO TAMAÑO QUE PUEDEN ASEGURAR UNA DISTRIBUCION GRADUAL DEL INGREDIENTE ACTIVO QUE CONTIENEN LAS UNIDADES QUE SE ESTAN RECUBRIENDO CON UNA CAPA DE POLIMERO BIOADHESIVO. LA COMPOSICION HACE POSIBLE MANTENER LA FUNCION DE CONTROL DE DISTRIBUCION SEPARADA DE LA FUNCION QUE PROPORCIONA BIOADHESION Y PUEDE ADAPTARSE ENTRE OTRAS A ADMINISTRACIONES ORALES, OCULARES, RECTALES, VAGINALES, NASALES O PERIODONTALES. TAMBIEN SE DESCRIBE UN PROCESO VENTAJOSO PARA LA FABRICACION DE LA COMPOSICION.
ES92109080T 1991-05-30 1992-05-29 Compuesto farmaceutico de liberacion controlada con propiedades bioadhesivas. Expired - Lifetime ES2091363T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911486A IT1250421B (it) 1991-05-30 1991-05-30 Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.

Publications (1)

Publication Number Publication Date
ES2091363T3 true ES2091363T3 (es) 1996-11-01

Family

ID=11360019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92109080T Expired - Lifetime ES2091363T3 (es) 1991-05-30 1992-05-29 Compuesto farmaceutico de liberacion controlada con propiedades bioadhesivas.

Country Status (9)

Country Link
US (1) US5472704A (es)
EP (1) EP0516141B1 (es)
JP (1) JPH07215843A (es)
AT (1) ATE141159T1 (es)
DE (1) DE69212710T2 (es)
DK (1) DK0516141T3 (es)
ES (1) ES2091363T3 (es)
GR (1) GR3020813T3 (es)
IT (1) IT1250421B (es)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036943A (en) 1990-03-22 2000-03-14 Ultradent Products, Inc. Methods for treating a person's teeth using sticky dental compositions in combination with passive-type dental trays
US5985249A (en) 1990-03-22 1999-11-16 Ultradent Products, Inc. Sticky dental compositions for adhering a passive-type dental tray over a person's teeth
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
DE69435002T2 (de) 1993-07-19 2008-03-20 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene Mittel enthaltend Taxol und einen nicht biodegradierbaren Träger und deren Verwendung
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
DE4404011A1 (de) * 1994-02-09 1995-08-10 Jenapharm Gmbh Neue, adhäsiv wirkende Zubereitungen für mit Flüssigkeit benetzte Oberflächen, Verfahren und Vorrichtung zur Erfassung der Adhäsionszeit diesbezüglicher Zubereitungen
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US6455304B1 (en) * 1994-07-01 2002-09-24 The Board Of Regents Of The University Of Oklahoma Hyaluronate synthase gene and uses thereof
US7091008B1 (en) 1994-07-01 2006-08-15 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase genes and expression thereof in Bacillus hosts
IT1273742B (it) * 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
WO1996021432A1 (en) * 1995-01-11 1996-07-18 Cygnus, Inc. Delivery of active substances by way of mucosal surfaces of pharyngeal and esophageal regions
ES2181868T3 (es) * 1995-02-28 2003-03-01 Aventis Pharma Inc Composicion farmaceutica para compuestos de piperidinoalcanol.
US6992107B1 (en) * 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
FR2737661B1 (fr) * 1995-08-08 1997-10-31 Mgi Pharma Inc Composition pharmaceutique sous forme de comprimes comprenant du chlorhydrate de pilocarpine
US5741525A (en) * 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
DE19600324A1 (de) * 1996-01-08 1997-07-10 Basf Ag Granulate für kosmetische und pharmazeutische Zubereitungen
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US20020018754A1 (en) 1999-03-15 2002-02-14 Paul Albert Sagel Shapes for tooth whitening strips
US6096328A (en) 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
DE69828193T2 (de) * 1997-10-31 2005-12-01 The Board Of Regents Of The University Of Oklahoma, Norman Hyaluronan synthase gen und seine verwendung
CN101113436B (zh) * 1997-10-31 2013-02-06 俄克拉何马大学董事会 透明质酸合酶基因及其应用
JPH11269064A (ja) * 1998-03-20 1999-10-05 Kowa Co 胃・十二指腸付着性医薬組成物
US6987023B2 (en) * 1998-04-02 2006-01-17 The Board Of Regents Of The University Of Oklahoma DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US7223571B2 (en) * 1998-04-02 2007-05-29 The Board Of Regents Of The Universtiy Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20060188966A1 (en) * 1998-04-02 2006-08-24 Deangelis Paul L Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
US20080108110A1 (en) * 1998-04-02 2008-05-08 Deangelis Paul L Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US7060469B2 (en) * 1998-04-02 2006-06-13 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
US7094581B2 (en) * 1998-10-26 2006-08-22 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthases and methods of making and using same
JP2002529064A (ja) 1998-11-11 2002-09-10 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ 多糖類シンターゼによるポリマーグラフティング
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
IN191482B (es) * 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
US7642071B2 (en) 1999-04-01 2010-01-05 The Board Of Regents Of The University Of Oklahoma Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
BR0012145A (pt) 1999-07-02 2002-04-30 Procter & Gamble Sistema de liberação de composições de tratamento oral, compreendendo resinas de organossiloxano usando uma fita de apoio removìvel
EP1206943B1 (en) 1999-08-26 2010-04-07 Takeda Pharmaceutical Company Limited Matrix adhering to nasal mucosa
US7534589B2 (en) * 1999-11-10 2009-05-19 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
EP1261316B1 (en) * 2000-02-28 2008-04-23 PharmaKodex Limited Device for the delivery of oral drugs
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US20050287638A1 (en) * 2000-04-25 2005-12-29 Weigel Paul H Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
PL360092A1 (en) 2000-06-28 2004-09-06 The Procter & Gamble Company Structures and compositions increasing the stability of peroxide actives
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
DE10107659B4 (de) * 2001-02-19 2008-03-13 Lts Lohmann Therapie-Systeme Ag Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
PT2060259E (pt) 2001-11-01 2010-04-26 Spectrum Pharmaceuticals Inc Composições médicas para o tratamento intravesical do cancro da bexiga
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US20070020737A1 (en) * 2001-12-03 2007-01-25 Pummill Philip E Hyaluronan synthases and methods of making and using same
US8226972B2 (en) * 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
WO2003105811A2 (en) * 2002-01-31 2003-12-24 Southwest Research Institute Controlled release compositions and methods for using same
BG65734B1 (bg) * 2002-02-22 2009-09-30 Био Терапютикс - Еоод Течен мукоадхезивен фармацевтичен състав
US8728510B1 (en) 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
IL164221A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
US20040115137A1 (en) * 2002-12-17 2004-06-17 Verrall Andrew P. Water-soluble film for oral administration
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040228918A1 (en) * 2003-01-02 2004-11-18 Chih-Ming Chen Granule modulating hydrogel system
WO2004060322A2 (en) * 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
DE10300325A1 (de) * 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
US20050118261A1 (en) * 2003-06-12 2005-06-02 Oien Hal J. Compositions and methods of administering doxepin to mucosal tissue
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
NZ580951A (en) * 2005-04-29 2011-06-30 Cubist Pharm Inc Therapeutic compositions
EP1965787B1 (en) * 2005-11-30 2013-04-10 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP4739452B2 (ja) 2006-09-20 2011-08-03 モノソル アールエックス リミテッド ライアビリティ カンパニー 発泡を減じる風味付与剤を含む喫食可能な水溶性フィルム
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
AR065913A1 (es) 2007-04-02 2009-07-08 Theracos Inc Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP3620153A1 (en) 2007-07-06 2020-03-11 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
CN101790311B (zh) 2007-08-23 2014-04-23 泰拉科斯有限公司 苄基苯衍生物及使用方法
CN105770878A (zh) 2007-10-12 2016-07-20 麻省理工学院 疫苗纳米技术
EP2312944B1 (en) 2008-07-15 2018-09-05 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
EP2324002B1 (en) 2008-08-22 2016-10-05 Theracos Sub, LLC Processes for the preparation of sglt2 inhibitors
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
EP2379561B1 (en) 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CA2800176C (en) 2010-05-24 2018-08-28 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
AU2011265294B2 (en) 2010-06-10 2015-01-22 Aquestive Therapeutics, Inc. Nanoparticle film delivery systems
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
RU2639447C2 (ru) 2010-10-08 2017-12-21 Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
WO2013188979A1 (en) 2012-06-20 2013-12-27 Frank Gu Mucoadhesive nanoparticle delivery system
EP2908798B1 (en) 2012-10-17 2018-08-22 The Procter and Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
JP2019519487A (ja) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US20200352991A1 (en) * 2017-07-27 2020-11-12 The Trustees Of Columbia University In The City Of New York Polymer films with antimicrobial agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699963A (en) * 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS57110254A (en) * 1980-12-29 1982-07-09 Teijin Ltd Coating agent of injured membrane part of oral cavity
EP0501523B1 (en) * 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US5196202A (en) * 1986-09-01 1993-03-23 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
WO1989010117A1 (en) * 1988-04-19 1989-11-02 Southwest Research Institute Controlled release of active ingredients from capsules having a salt sensitive shell material
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules

Also Published As

Publication number Publication date
DE69212710D1 (de) 1996-09-19
JPH07215843A (ja) 1995-08-15
DK0516141T3 (da) 1996-09-02
ITMI911486A1 (it) 1992-11-30
EP0516141B1 (en) 1996-08-14
ITMI911486A0 (it) 1991-05-30
DE69212710T2 (de) 1996-12-19
IT1250421B (it) 1995-04-07
EP0516141A1 (en) 1992-12-02
US5472704A (en) 1995-12-05
ATE141159T1 (de) 1996-08-15
GR3020813T3 (en) 1996-11-30

Similar Documents

Publication Publication Date Title
ES2091363T3 (es) Compuesto farmaceutico de liberacion controlada con propiedades bioadhesivas.
BR9304760A (pt) Composiçao, método para liberar um medicamento a uma ferida e bandagem
AR004134A1 (es) Derivados 2-amino-6-anilino-purina y procedimiento y nuevos intermediarios para su preparacion, formulaciones farmaceuticas que comprenden talesderivados y el uso de estos derivados como medicamentos.
FR1409033T (fr) Adhesif renfermant un medicament
ES2159591T3 (es) Composicion de liberacion controlada.
AR229184A1 (es) Envase dispensador para contener y preservar una pluralidad de grapas quirurgicas para ligadura esteriles,secas e hidrolizables
ES2145913T3 (es) Inhibidores de metaloproteasas.
ES2180251T3 (es) Comprimido revestido con polimero, que contiene amoxicilina y clavulanato.
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
AR015349A1 (es) Nuevas modificaciones cristalinas del 2-amino-4-(4-fluorbencilamino)-1-etoxicarbonil-aminobenceno y procedimiento para prepararlos, utilizacion de losmismas y medicamento que las contienen
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
ES2107203T3 (es) Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido.
ES2171283T3 (es) Sistema de administracion de farmacos para dos o mas substancias activas.
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
AR021800A1 (es) Implantes medicinales recubiertos con polimeros o una mezcla de polimeros solucion esteril que contiene tales polimeros y empleo de los mismos yprocedimiento para la preparacion de estos implantes medicinales.
GT199800152A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
KR910009241A (ko) 치근막 질환 치료용 서방성 조성물
SE8701406D0 (sv) Aromatiska foreningar, deras framtellningsforfarande och deras anvendning inom human- och veterinermedicinen och inom kosmetiken
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
AR013613A1 (es) MICROESFERAS FARMACÉUTICAS DE ÁCIDO VALPROICO PARA LA ADMINISTRACIoN ORAL, PROCEDIMIENTO PARA PREPARARLAS Y FORMAS FARMACÉUTICAS QUE LAS CONTIENEN
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 516141

Country of ref document: ES